Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
about
Persistent pharmacokinetic challenges to pediatric drug developmentCritical evaluation of key evidence on the human health hazards of exposure to bisphenol A.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.Ontogeny of midazolam glucuronidation in preterm infants.Human hepatic UGT2B15 developmental expression.The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liverUpregulation of Ugt1a genes in placentas and fetal livers in a murine model of assisted reproductionPlacental profiling of UGT1A enzyme expression and activity and interactions with preeclampsia at term.Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenAge-Dependent Hepatic UDP-Glucuronosyltransferase Gene Expression and Activity in Children.Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies.Second-generation antiepileptic drugs and pregnancy: a guide for clinicians.Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis.Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.Safety evaluation of ractopamineImpact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.The effects of UDP-sugars, UDP and Mg2+on uridine diphosphate glucuronosyltransferase activity in human liver microsomes.Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.Allometry Is a Reasonable Choice in Pediatric Drug Development.
P2860
Q27023912-7B002A35-E88D-44F7-8E2D-1B681D36DF53Q30396069-43E3EF34-1BD6-4C29-8DB0-0A1152D09654Q33451969-5194EB72-2CEF-4024-9E05-8CD29D4FE075Q33587843-AFFFCAE6-0C6F-4707-BD03-D93ACD845F6CQ34737080-49895F07-60CF-42EB-95E5-9D4B599D2E00Q34857030-9104C58E-C6B0-4996-8668-F0B1026EF6F5Q35643443-A09C2078-055F-4F22-AF0C-BAD48E4B7E50Q35952402-C01C008C-D8EC-4801-91D3-5C9FDD54917FQ36057407-A66C5EE9-9A2F-4028-BC78-26F48A7E2671Q36117928-E64A8753-5F06-47CC-990A-B63910C80D2FQ36501845-9115D4B3-2141-41BB-8BE9-43F70D57E10BQ37279407-F3979C07-C2B5-49D4-95BD-C129468BD0E8Q37416072-0C60BE6A-26F1-4E8B-B38E-A59D169AF17FQ37731228-65FFAB8B-5C94-4721-B7C1-CB591D2264B2Q37872786-C78A462F-39FF-4E40-91C2-846D62353657Q38003479-8F4F35B6-D081-4CC2-B696-CC8F25E2D4A8Q38014890-BC722BDE-806F-408C-A0D6-7C715278E0CBQ38386709-37AF33B9-90E0-4A0B-A9B1-4DED8A507C31Q39870288-B71DC95B-05DC-46B3-AA00-D87A1D0ABB95Q40612167-3FC57D0A-4101-44DD-9F3A-F14870172A82Q41063905-0882F732-9632-4AB9-BE29-C922837625FAQ42001999-66F0F231-23B1-4165-9E80-0398DC8A60A6Q47146554-D7E90427-031A-48B8-9EAD-119051B0E7F7Q47310442-25555271-181E-4B3E-BEAD-260EFB0C4947Q50226493-099EE1E9-2CD2-4631-A355-16CC18477DDCQ51140860-79BE078B-0B6B-46C5-A50D-FCF806402683Q54771792-1E971F7A-946D-4547-9D2F-0A4924C506E2
P2860
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@en
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@nl
type
label
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@en
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@nl
prefLabel
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@en
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@nl
P356
P1476
Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4.
@en
P2093
Abby C Collier
Shogo J Miyagi
P304
P356
10.1124/DMD.107.015214
P577
2007-06-07T00:00:00Z